Table of Contents Author Guidelines Submit a Manuscript
Journal of Obesity
Volume 2011, Article ID 179674, 18 pages
http://dx.doi.org/10.1155/2011/179674
Review Article

Pharmacotherapies for Obesity: Past, Current, and Future Therapies

Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Alfred Centre, Commercial Road, Melbourne, VIC 3004, Australia

Received 4 August 2010; Accepted 24 September 2010

Academic Editor: A. Halpern

Copyright © 2011 Lisa L. Ioannides-Demos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [133 citations]

The following is the list of published articles that have cited the current article.

  • Jagjit Singh, and Rajiv Kumar, “Phentermine-topiramate: First combination drug for obesity.,” International journal of applied & basic medical research, vol. 5, no. 2, pp. 157–8, . View at Publisher · View at Google Scholar
  • Bruno Bariohay, Julien A. Roux, Marion S. Bonnet, Michel Dallaporta, and Jean-Denis Troadec, “An Update in the Management of Obesity: The Weight of CNS Targets,” Recent Patents on CNS Drug Discovery, vol. 6, no. 3, pp. 164–180, 2011. View at Publisher · View at Google Scholar
  • Yerly, and Vachiéry, “Anorectic drugs and cardiovascular diseases: Les liaisons dangereuses,” Reanimation, vol. 20, no. 5, pp. 424–435, 2011. View at Publisher · View at Google Scholar
  • Martos-Moreno, and Argente, “Paediatric obesities: From childhood to adolescence,” Anales de Pediatria, vol. 75, no. 1, pp. 63–e23, 2011. View at Publisher · View at Google Scholar
  • John P. Kelly, “Cathinone derivatives: A review of their chemistry, pharmacology and toxicology,” Drug Testing and Analysis, vol. 3, no. 7-8, pp. 439–453, 2011. View at Publisher · View at Google Scholar
  • J. Audrain-McGovern, and N. L. Benowitz, “Cigarette Smoking, Nicotine, and Body Weight,” Clinical Pharmacology & Therapeutics, vol. 90, no. 1, pp. 164–168, 2011. View at Publisher · View at Google Scholar
  • Barham K. Abu Dayyeh, and Lee M. Kaplan, “Medical Therapy for Obesity,” Gastrointestinal Endoscopy Clinics of North America, vol. 21, no. 2, pp. 203–212, 2011. View at Publisher · View at Google Scholar
  • Hazem Shamseddeen, Jorge Zelada Getty, Isam N. Hamdallah, and Mohamed R. Ali, “Epidemiology and Economic Impact of Obesity and Type 2 Diabetes,” Surgical Clinics of North America, vol. 91, no. 6, pp. 1163–+, 2011. View at Publisher · View at Google Scholar
  • Francisco José Roma Paumgartten, “Long-term health benefits of appetite suppressants remain unproven,” Revista de Saude Publica, vol. 45, no. 6, pp. 1192–1196, 2011. View at Publisher · View at Google Scholar
  • Beatriz Hemo, Ronit Endevelt, Avi Porath, Meir J. Stampfer, and Iris Shai, “Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals,” Diabetes Research And Clinical Practice, vol. 94, no. 2, pp. 269–275, 2011. View at Publisher · View at Google Scholar
  • David R. Janero, Loren Lindsley, Venkata Kiran Vemuri, and Alexandros Makriyannis, “Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk,” Expert Opinion On Drug Discovery, vol. 6, no. 10, pp. 995–1025, 2011. View at Publisher · View at Google Scholar
  • Francisco José Roma Paumgartten, “Long-term health benefits of appetite suppressants remain unproven,” Revista de Saude Publica, vol. 45, no. 6, pp. 1192–1196, 2011. View at Publisher · View at Google Scholar
  • Federica Guaraldi, Uberto Pagotto, and Renato Pasquali, “Predictors of weight loss and maintenance in patients treated with antiobesity drugs.,” Diabetes, metabolic syndrome and obesity : targets and therapy, vol. 4, pp. 229–43, 2011. View at Publisher · View at Google Scholar
  • Caroline M Apovian, “Management of diabetes across the course of disease: minimizing obesity-associated complications.,” Diabetes, metabolic syndrome and obesity : targets and therapy, vol. 4, pp. 353–69, 2011. View at Publisher · View at Google Scholar
  • Kazuko Masuo, “Treatments for obesity-related hypertension,” Current Hypertension Reviews, vol. 7, no. 3, pp. 184–199, 2011. View at Publisher · View at Google Scholar
  • Sharanabasayyaswamy B. Hiremath, and Naveen Kumar Madalageri, “Zonisamide in the treatment of obesity: A meta-analysis,” Journal of Applied Pharmaceutical Science, vol. 2, no. 9, pp. 113–118, 2012. View at Publisher · View at Google Scholar
  • Marcelo O. Dietrich, and Tamas L. Horvath, “Limitations in anti-obesity drug development: The critical role of hunger-promoting neurons,” Nature Reviews Drug Discovery, vol. 11, no. 9, pp. 675–691, 2012. View at Publisher · View at Google Scholar
  • Karen E. Stewart, and James L. Levenson, “Psychological and Psychiatric Aspects of Treatment of Obesity and Nonalcoholic Fatty Liver Disease,” Clinics In Liver Disease, vol. 16, no. 3, pp. 615–+, 2012. View at Publisher · View at Google Scholar
  • Dominic Ammann, Jenna M. McLaren, Dimitri Gerostamoulos, and Jochen Beyer, “Detection and Quantification of New Designer Drugs in Human Blood: Part 2 Designer Cathinones,” Journal Of Analytical Toxicology, vol. 36, no. 6, pp. 381–389, 2012. View at Publisher · View at Google Scholar
  • Jillian M. Hagel, Raz Krizevski, Frédéric Marsolais, Efraim Lewinsohn, and Peter J. Facchini, “Biosynthesis of amphetamine analogs in plants,” Trends in Plant Science, vol. 17, no. 7, pp. 404–412, 2012. View at Publisher · View at Google Scholar
  • Yueshan Hu, Erik A. Ehli, Julie Kittelsrud, Patrick J. Ronan, Karen Munger, Terry Downey, Krista Bohlen, Leah Callahan, Vicki Munson, Mike Jahnke, Lindsey L. Marshall, Kelly Nelson, Patricia Huizenga, Ryan Hansen, Timothy J. Soundy, and Gareth E. Davies, “Lipid-lowering effect of berberine in human subjects and rats,” Phytomedicine, vol. 19, no. 10, pp. 861–867, 2012. View at Publisher · View at Google Scholar
  • Luiz Henrique Guerreiro, Daniel Da Silva, Eduardo Ricci-Junior, Wendell Girard-Dias, Camile Moreira Mascarenhas, Mauro Sola-Penna, Kildare Miranda, and Luis Mauricio T. R. Lima, “Polymeric particles for the controlled release of human amylin,” Colloids and Surfaces B-Biointerfaces, vol. 94, pp. 101–106, 2012. View at Publisher · View at Google Scholar
  • Debasis Bagchi, Harry Preuss, Susan Schwartz, and David Savastano, “History and Regulation of Prescription and Over-the-Counter Weight Loss Drugs,” Obesity, pp. 313–324, 2012. View at Publisher · View at Google Scholar
  • Matthias Van Hul, Florea Lupu, Tom Dresselaers, Johan Buyse, and H. Roger Lijnen, “Matrix metalloproteinase inhibition affects adipose tissue mass in obese mice,” Clinical And Experimental Pharmacology And Physiology, vol. 39, no. 6, pp. 544–550, 2012. View at Publisher · View at Google Scholar
  • A. J. Garber, “Obesity and type 2 diabetes: which patients are at risk?,” Diabetes Obesity & Metabolism, vol. 14, no. 5, pp. 399–408, 2012. View at Publisher · View at Google Scholar
  • E. Kirilly, X. Gonda, and G. Bagdy, “CB1 receptor antagonists: new discoveries leading to new perspectives,” Acta Physiologica, vol. 205, no. 1, pp. 41–60, 2012. View at Publisher · View at Google Scholar
  • Caroline M. Apovian, and Noyan Gokce, “Obesity and Cardiovascular Disease,” Circulation, vol. 125, no. 9, pp. 1178–1182, 2012. View at Publisher · View at Google Scholar
  • David R. Janero, “Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists,” Expert Opinion On Emerging Drugs, vol. 17, no. 1, pp. 17–29, 2012. View at Publisher · View at Google Scholar
  • Kwang-Mook Jung, Jason R. Clapper, Jin Fu, Giuseppe D'Agostino, Ana Guijarro, Dean Thongkham, Agnesa Avanesian, Giuseppe Astarita, Nicholas V. DiPatrizio, Andrea Frontini, Saverio Cinti, Sabrina Diano, and Daniele Piomelli, “2-Arachidonoylglycerol Signaling in Forebrain Regulates Systemic Energy Metabolism,” Cell Metabolism, vol. 15, no. 3, pp. 299–310, 2012. View at Publisher · View at Google Scholar
  • E. Kirilly, X. Gonda, and G. Bagdy, “CB1 receptor antagonists: new discoveries leading to new perspectives,” Acta Physiologica, vol. 205, no. 1, pp. 41–60, 2012. View at Publisher · View at Google Scholar
  • Domenica M. Rubino, and Kishore M. Gadde, “A review of topiramate and phentermine: a combined therapeutic approach for obesity,” Clinical Lipidology, vol. 7, no. 1, pp. 13–25, 2012. View at Publisher · View at Google Scholar
  • Barbara E. Corkey, “Diabetes: Have We Got It All Wrong?,” Diabetes Care, vol. 35, no. 12, pp. 2432–2437, 2012. View at Publisher · View at Google Scholar
  • E. M. Kaptein, L. S. Chan, and J. S. Kaptein, “Assessment of maximum weight change and duration of therapeutic effect for non-surgical treatment of obesity using an exponential model,” Eating And Weight Disorders-Studies On Anorexia Bulimia And Obesity, vol. 17, no. 4, pp. E234–E243, 2012. View at Publisher · View at Google Scholar
  • Susan L. McElroy, and Paul E. Keck Jr., “Obesity in bipolar disorder: An overview,” Current Psychiatry Reports, vol. 14, no. 6, pp. 650–658, 2012. View at Publisher · View at Google Scholar
  • Vojtech Hainer, and Irena Aldhoon Hainerová, “Do we need anti-obesity drugs?,” Diabetes/Metabolism Research and Reviews, vol. 28, pp. 8–20, 2012. View at Publisher · View at Google Scholar
  • C K Boughton, and K G Murphy, “Can Neuropeptides Treat Obesity? A review of neuropeptides and their potential role in the treatment of obesity.,” British Journal of Pharmacology, 2012. View at Publisher · View at Google Scholar
  • Judith Aron-Wisnewsky, Joel Doré, and Karine Clement, “The importance of the gut microbiota after bariatric surgery,” Nature Reviews Gastroenterology and Hepatology, vol. 9, no. 10, pp. 590–598, 2012. View at Publisher · View at Google Scholar
  • Davis, Castelo-Branco, Chedraui, Lumsden, Nappi, Shah, and Villaseca, “Understanding weight gain at menopause,” Climacteric, vol. 15, no. 5, pp. 419–429, 2012. View at Publisher · View at Google Scholar
  • Susan L Mcelroy, Anna I Guerdjikova, Nicole Mori, and Anne M O'Melia, “Current pharmacotherapy options for bulimia nervosa and binge eating disorder,” Expert Opinion on Pharmacotherapy, vol. 13, no. 14, pp. 2015–2026, 2012. View at Publisher · View at Google Scholar
  • Susan L. McElroy, Anna I. Guerdjikova, Nicole Mori, and Anne M. O'Melia, “Pharmacological management of binge eating disorder: current and emerging treatment options,” Therapeutics And Clinical Risk Management, vol. 8, pp. 219–241, 2012. View at Publisher · View at Google Scholar
  • Marietta Charakida, and Nicholas Finer, “Drug Treatment of Obesity in Cardiovascular Disease,” American Journal Of Cardiovascular Drugs, vol. 12, no. 2, pp. 93–104, 2012. View at Publisher · View at Google Scholar
  • Rebeca Carter, Angelina Mouralidarane, Junpei Soeda, Jude Oben, and Shuvra Ray, “Recent advancements in drug treatment of obesity,” Clinical Medicine, Journal of the Royal College of Physicians of London, vol. 12, no. 5, pp. 456–460, 2012. View at Publisher · View at Google Scholar
  • Joanna Tkaczuk-Włach, Rafał Włach, Małgorzata Sobstyl, and Grzegorz Jakiel, “Otyłść w okresie około- i pomenopauzalnym,” Przeglad Menopauzalny, vol. 16, no. 6, pp. 514–517, 2012. View at Publisher · View at Google Scholar
  • Shuai Wang, and Daoquan Peng, “Regulation of adipocyte autophagy the potential anti-obesity mechanism of high density lipoprotein and ApolipoproteinA-I,” Lipids in Health and Disease, vol. 11, 2012. View at Publisher · View at Google Scholar
  • M. Chilton, A. Dunkley, P. Carter, M. J. Davies, K. Khunti, and L. J. Gray, “The effect of antiobesity drugs on waist circumference: a mixed treatment comparison,” Diabetes, Obesity and Metabolism, 2013. View at Publisher · View at Google Scholar
  • B Wang, J Avorn, and As Kesselheim, “Clinical and Regulatory Features of Drugs Not Initially Approved by the FDA,” Clinical Pharmacology & Therapeutics, 2013. View at Publisher · View at Google Scholar
  • Mark Delegge, and Jeanette Newton Keithpp. 19–37, 2013. View at Publisher · View at Google Scholar
  • Maria Rita De Giorgio, Mayumi Yoshioka, Isabelle Riedl, Olivier Moreault, Rose-Guerline Cherizol, Aftab Ali Shah, Nikolaus Blin, Denis Richard, and Jonny St-Amand, “ Trefoil factor family member 2 ( Tff2 ) KO mice are protected from high-fat diet-induced obesity ,” Obesity, vol. 21, no. 7, pp. 1389–1395, 2013. View at Publisher · View at Google Scholar
  • E J Hendricks, M Srisurapanont, S L Schmidt, M Haggard, S Souter, C L Mitchell, D G De Marco, M J Hendricks, Y Istratiy, and F L Greenway, “Addiction potential of phentermine prescribed during long-term treatment of obesity,” International Journal of Obesity, vol. 38, no. 2, pp. 292–298, 2013. View at Publisher · View at Google Scholar
  • J. Fichna, A. Sibaev, M. Sałaga, M. Sobczak, and M. Storr, “The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice,” Neurogastroenterology & Motility, vol. 25, no. 8, pp. e550–e559, 2013. View at Publisher · View at Google Scholar
  • Hoyoung An, Hyunjoo Sohn, and Seockhoon Chung, “Phentermine, sibutramine and affective disorders,” Clinical Psychopharmacology and Neuroscience, vol. 11, no. 1, pp. 7–12, 2013. View at Publisher · View at Google Scholar
  • Wei Chen, Zhenhua Chen, Nina Xue, Zhibing Zheng, Song Li, and LiLi Wang, “Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 386, no. 8, pp. 721–732, 2013. View at Publisher · View at Google Scholar
  • Mario Alvarado, Juan Decara, Maria Jesus Luque, Laura Hernandez-Folgado, Maria Gomez-Canas, Maria Gomez-Ruiz, Javier Fernandez-Ruiz, Jose Elguero, Nadine Jagerovic, Antonia Serrano, Pilar Goya, and Fernando Rodriguez de Fonseca, “Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21,” Bioorganic & Medicinal Chemistry, vol. 21, no. 7, pp. 1708–1716, 2013. View at Publisher · View at Google Scholar
  • Guido Di Dalmazi, Valentina Vicennati, and Renato Pasquali, “The unrelenting fall of the pharmacological treatment of obesity,” Endocrine, vol. 44, no. 3, pp. 598–609, 2013. View at Publisher · View at Google Scholar
  • J. Gras, “Cetilistat For The Treatment Of Obesity,” Drugs of Today, vol. 49, no. 12, pp. 755–759, 2013. View at Publisher · View at Google Scholar
  • H Suplicy, C L Boguszewski, C M C dos Santos, Md D de Figueiredo, D R Cunha, and R Radominski, “A comparative study of five centrally acting drugs on the pharmacological treatment of obesity,” International Journal of Obesity, 2013. View at Publisher · View at Google Scholar
  • Matthias Van Hul, Dries Bauters, and Roger H. Lijnen, “Differential effects of a gelatinase inhibitor on adipocyte differentiation and adipose tissue development,” Clinical and Experimental Pharmacology and Physiology, vol. 40, no. 10, pp. 689–697, 2013. View at Publisher · View at Google Scholar
  • Csupor, Boros, Dankó, Veres, Szendrei, and Hohmann, “Rapid identification of sibutramine in dietary supplements using a stepwise approach,” Pharmazie, vol. 68, no. 1, pp. 15–18, 2013. View at Publisher · View at Google Scholar
  • R. Sherafat-Kazemzadeh, and S. Z. Yanovski, “Pharmacotherapy for childhood obesity: present and future prospects,” International Journal of Obesity, vol. 37, no. 1, pp. 1–15, 2013. View at Publisher · View at Google Scholar
  • Blake A. Gosnell, Catherine M. Kotz, Charles J. Billington, and Allen S. Levinepp. 1149–1153, 2013. View at Publisher · View at Google Scholar
  • Dimitrios N. Kiortsis, “A review of the metabolic effects of controlled-release Phentermine/Topiramate,” Hormones, vol. 12, no. 4, pp. 507–516, 2013. View at Publisher · View at Google Scholar
  • Bashar M. Attar, and David H. Van Thiel, “Current Concepts and Management Approaches in Nonalcoholic Fatty Liver Disease,” The Scientific World Journal, vol. 2013, pp. 1–10, 2013. View at Publisher · View at Google Scholar
  • Hyun Ok Kim, Jung Ah Lee, Hee Won Suh, Young Sik Kim, Bum Soo Kim, Eun Sook Ahn, Young Jun Roh, Seong Gil Jung, Jin Mok Kim, Moon Kuk Kang, In Soon Ahn, and Young Gyu Park, “Postmarketing Surveillance Study of the Efficacy and Safety of Phentermine in Patients with Obesity,” Korean Journal of Family Medicine, vol. 34, no. 5, pp. 298, 2013. View at Publisher · View at Google Scholar
  • E. Panzhinskiy, J. Ren, and S. Nair, “Pharmacological Inhibition of Protein Tyrosine Phosphatase 1B: A Promising Strategy for the Treatment of Obesity and Type 2 Diabetes Mellitus,” Current Medicinal Chemistry, vol. 20, no. 21, pp. 2609–2625, 2013. View at Publisher · View at Google Scholar
  • Gina Cosentino, Ariane O. Conrad, and Gabriel I. Uwaifo, “Phentermine and topiramate for the management of obesity: a review,” Drug Design Development and Therapy, vol. 7, pp. 267–278, 2013. View at Publisher · View at Google Scholar
  • Lucio Cabrerizo García, Ana Ramos-Leví, Carmen Moreno Lopera, and Miguel A. Rubio Herrera, “Update on pharmacology of obesity: Benefts and risks,” Nutricion Hospitalaria, vol. 28, no. 5, pp. 121–127, 2013. View at Publisher · View at Google Scholar
  • Rickard E. Malmström, Alessandra Ferrario, Alexander E. Finlayson, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Iñaki Gutiérrez-Ibarluzea, Alan Haycox, Krystyna Hviding, Harald Herholz, Mikael Hoffmann, Brian B. Godman, Saira Jan, Jan Jones, Roberta Joppi, Marija Kalaba, Christina Kvalheim, Ott Laius, Irene Langner, Julie Lonsdale, Sven-Åke Lööv, Kamila Malinowska, Eduard Diogene, Laura McCullagh, Ken Paterson, Vanda Markovic-Pekovic, Andrew Martin, Jutta Piessnegger, Gisbert Selke, Catherine Sermet, Steven Simoens, Cankat Tulunay, Dominik Tomek, Christoph Baumgärte, Luka Voncina, Vera Vlahovic-Palcevski, Janet Wale, Michael Wilcock, Magdalena Wladysiuk, Menno Van Woerkom, Corrine Zara, Lars L. Gustafsson, Marion Bennie, Iain Bishop, Anna Brzezinska, Anna Bucsics, and Stephen Campbell, “Dabigatran - A case history demonstrating the need for comprehensive approaches to optimize the use of new drugs,” Frontiers in Pharmacology, vol. 4, 2013. View at Publisher · View at Google Scholar
  • Domenico Italiano, Edoardo Spina, and Jose de Leon, “Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants,” Expert Opinion on Drug Metabolism & Toxicology, pp. 1–33, 2014. View at Publisher · View at Google Scholar
  • Mauricio Berriel Diaz, Stephan Herzig, and Alexandros Vegiopoulos, “Thermogenic adipocytes From cells to physiology and medicine,” Metabolism, 2014. View at Publisher · View at Google Scholar
  • Martin F. Casey, and Jeffrey I. Mechanick, “Anti-Obesity Agents and the US Food and Drug Administration,” Current Obesity Reports, 2014. View at Publisher · View at Google Scholar
  • J. Gras, “BELORANIB HEMIOXALATE Methionine aminopeptidase 2 inhibitor Treatment of obesity,” Drugs of The Future, vol. 39, no. 6, pp. 385–389, 2014. View at Publisher · View at Google Scholar
  • Antonella Rocca, Virgilio Mattoli, Barbara Mazzolai, and Gianni Ciofani, “Cerium Oxide Nanoparticles Inhibit Adipogenesis in Rat Mesenchymal Stem Cells: Potential Therapeutic Implications,” Pharmaceutical Research, 2014. View at Publisher · View at Google Scholar
  • Sonja K. Billes, Puspha Sinnayah, and Michael A. Cowley, “Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss,” Pharmacological Research, 2014. View at Publisher · View at Google Scholar
  • Eleni Koutroumanidou, and Olga Pagonopoulou, “Combination of very low energy diets and pharmacotherapy in the treatment of obesity: meta-analysis of published data,” Diabetes-Metabolism Research and Reviews, vol. 30, no. 3, pp. 165–174, 2014. View at Publisher · View at Google Scholar
  • Kai He, Xiaoli Ye, Hao Wu, YanZhi Wang, Zongyao Zou, Na Ning, Yinran Hu, Biao Chen, Xuedong Fang, and Xuegang Li, “The Safety and Anti-Hypercholesterolemic Effect of Coptisine in Syrian Golden Hamsters,” Lipids, 2014. View at Publisher · View at Google Scholar
  • So-Hyeon Baek, Hea-Jong Chung, Heui-Kwan Lee, Roshan D'Souza, Youngju Jeon, Hyeon-Jin Kim, Soon-Jong Kweon, and Seong-Tshool Hong, “Treatment of obesity with the resveratrol-enriched rice DJ-526,” Scientific Reports, vol. 4, 2014. View at Publisher · View at Google Scholar
  • Mark Donaldson, Jason H. Goodchild, and Jane Ziegler, “Dental considerations for patients taking weight-loss medications,” The Journal of the American Dental Association, vol. 145, no. 1, pp. 70–74, 2014. View at Publisher · View at Google Scholar
  • Ryan T. Hurt, Jon O. Ebbert, Darrell R. Schroeder, Ivana T. Croghan, Brent A. Bauer, Stephen A. McClave, John M. Miles, and Craig J. McClain, “L-Arginine for the Treatment of Centrally Obese Subjects: A Pilot Study,” Journal of Dietary Supplements, pp. 140110103738004, 2014. View at Publisher · View at Google Scholar
  • Assumpta Caixas, Lara Albert, Ismael Capel, and Mercedes Rigla, “Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date,” Drug Design Development and Therapy, vol. 8, pp. 1419–1427, 2014. View at Publisher · View at Google Scholar
  • Gabriel Á. Martos-Moreno, Vicente Barrios, María T. Muñoz-Calvo, Jesús Pozo, Julie A. Chowen, and Jesús Argente, “Principles and pitfalls in the differential diagnosis and management of childhood obesities,” Advances in Nutrition, vol. 5, no. 3, pp. 299–305, 2014. View at Publisher · View at Google Scholar
  • Mark Donaldson, Jason H. Goodchild, and Jane Ziegler, “Dental considerations for patients taking weight-loss medications,” Journal of the American Dental Association, vol. 145, no. 1, pp. 70–74, 2014. View at Publisher · View at Google Scholar
  • Gras, “Beloranib hemioxalate. Methionine aminopeptidase 2 inhibitor, Treatment of obesity,” Drugs of the Future, vol. 39, no. 6, pp. 385–389, 2014. View at Publisher · View at Google Scholar
  • Esther C.Y. Woon, and Joel D.W. Toh, “Antiobesity Effects of Natural Products from an Epigenetic Perspective,” vol. 41, pp. 161–193, 2014. View at Publisher · View at Google Scholar
  • Sani M. Roy, Stacy Rustico, and Bassil Kublaoui, “Prevention and Treatment of Childhood Obesity and Metabolic Syndrome,” Metabolic Syndrome, pp. 1–25, 2015. View at Publisher · View at Google Scholar
  • Herman Soto-Molina, Mariel Pizarro-Castellanos, Juana Rosado-Pérez, Antonio Rizzoli-Córdoba, Eleazar Lara-Padilla, Cecilia Fernández Del Valle-Laisequilla, and Juan Gerardo Reyes-García, “Six-month efficacy and safety of amfepramone in obese Mexican patients: A double-blinded, randomized, controlled trial,” International Journal of Clinical Pharmacology and Therapeutics, vol. 53, no. 7, pp. 541–549, 2015. View at Publisher · View at Google Scholar
  • Andrew J. Krentz, Ken Fujioka, and Marcus Hompesch, “Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide,” Drugs, 2015. View at Publisher · View at Google Scholar
  • Da Silva, Montaldi, Dos Santos, and Takahashi, “Evaluation of the toxic activity of anorectic diethylpropion in Chinese hamster ovary cells,” Human and Experimental Toxicology, vol. 34, no. 3, pp. 300–307, 2015. View at Publisher · View at Google Scholar
  • Cassie L. Boland, John Brock Harris, and Kira B. Harris, “Pharmacological Management of Obesity in Pediatric Patients,” Annals of Pharmacotherapy, vol. 49, no. 2, pp. 220–232, 2015. View at Publisher · View at Google Scholar
  • Nicholas V. DiPatrizio, and Daniele Piomelli, “Intestinal lipid-derived signals that sense dietary fat,” Journal of Clinical Investigation, 2015. View at Publisher · View at Google Scholar
  • Parveen Kumar, and Uma Bhandari, “Obesity pharmacotherapy: Current status,” EXCLI Journal, vol. 14, pp. 290–293, 2015. View at Publisher · View at Google Scholar
  • Prasenjit Manna, and Sushil K. Jain, “Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies,” Metabolic Syndrome and Related Disorders, vol. 13, no. 10, pp. 423–444, 2015. View at Publisher · View at Google Scholar
  • H. Ikeda, C. Ardianto, N. Yonemochi, L. Yang, T. Ohashi, M. Ikegami, H. Nagase, and J. Kamei, “Inhibition of opioid systems in the hypothalamus as well as the mesolimbic area suppresses feeding behavior of mice,” Neuroscience, vol. 311, pp. 9–21, 2015. View at Publisher · View at Google Scholar
  • V. Salem, C. Izzi-Engbeaya, C. Coello, D. B. Thomas, E. S. Chambers, A. N. Comninos, A. Buckley, Z. Win, A. Al-Nahhas, E. A. Rabiner, R. N. Gunn, H. Budge, M. E. Symonds, S. R. Bloom, T. M. Tan, and W. S. Dhillo, “Glucagon increases energy expenditure independently of brown adipose tissue activation in humans,” Diabetes, Obesity and Metabolism, vol. 18, no. 1, pp. 72–81, 2015. View at Publisher · View at Google Scholar
  • Amal A. Bajrai, Essam Ezzeldin, Khalid A. Al-Rashood, Mohammad Raish, and Muzaffar Iqbal, “A Validated UPLC–MS-MS Assay for the Rapid Determination of Lorcaserin in Plasma and Brain Tissue Samples,” Journal of Analytical Toxicology, vol. 40, no. 2, pp. 133–139, 2015. View at Publisher · View at Google Scholar
  • Jan Peter Yska, Douwe H. van der Meer, Albert R. Dreijer, Willeke Eilander, Jan A. Apers, Marloes Emous, Erik R. E. Totté, Bob Wilffert, and Eric N. van Roon, “Influence of bariatric surgery on the use of medication,” European Journal of Clinical Pharmacology, 2015. View at Publisher · View at Google Scholar
  • Andrea Lenzi, Silvia Migliaccio, and Lorenzo Maria Doninipp. 1–350, 2015. View at Publisher · View at Google Scholar
  • Valentina Lo Preiato, Elena Daniela Serban, Renato Pasquali, and Uberto Pagottopp. 261–270, 2015. View at Publisher · View at Google Scholar
  • Ashish Kumar Kakkar, and Neha Dahiya, “Drug treatment of obesity: Current status and future prospects,” European Journal of Internal Medicine, 2015. View at Publisher · View at Google Scholar
  • Nathalia Romanelli Vicente Dragano, and Anne y Castro Marquespp. 131–145, 2015. View at Publisher · View at Google Scholar
  • Abdulmaged M. Traish, and James T. Trussler, “Effects of Lifestyle Changes and Testosterone Therapy on Erectile Function,” Contemporary Treatment of Erectile Dysfunction, pp. 101–130, 2016. View at Publisher · View at Google Scholar
  • Vanessa Point, Anais Bénarouche, Julie Zarillo, Alexandre Guy, Romain Magnez, Laurence Fonseca, Brigitt Raux, Julien Leclaire, Gérard Buono, Frédéric Fotiadu, Thierry Durand, Frédéric Carrière, Carole Vaysse, Leslie Couëdelo, and Jean-François Cavalier, “Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis,” European Journal of Medicinal Chemistry, 2016. View at Publisher · View at Google Scholar
  • Sivakumar Annamalai, Lavanya Mohanam, Alwin, and Venkataraman Prabhu, “Effect of combination therapy of melatonin and orlistat on high fat diet induced changes in lipid profiles and liver function parameters in serum of rats,” Obesity Medicine, vol. 2, pp. 41–45, 2016. View at Publisher · View at Google Scholar
  • Neil Wright, and Jerry Wales, “Assessment and management of severely obese children and adolescents,” Archives of Disease in Childhood, vol. 101, no. 12, pp. 1161–1167, 2016. View at Publisher · View at Google Scholar
  • Huijuan Zhu, Xiangqing Wang, Hui Pan, Yufei Dai, Naishi Li, Linjie Wang, Hongbo Yang, and Fengying Gong, “The Mechanism by Which Safflower Yellow Decreases Body Fat Mass and Improves Insulin Sensitivity in HFD-Induced Obese Mice,” Frontiers in Pharmacology, vol. 7, 2016. View at Publisher · View at Google Scholar
  • Shuming Kou, Zongyao Zou, Yinran Hu, Xiaoli Ye, Kai He, Min Feng, Bing Han, and Xuegang Li, “Hypolipidemic Effects of Alkaloids from Rhizoma Coptidis in Diet-Induced Hyperlipidemic Hamsters,” Planta Medica, vol. 82, no. 8, pp. 690–697, 2016. View at Publisher · View at Google Scholar
  • Yo-Han Han, Ji-Ye Kee, Jinbong Park, Hye-Lin Kim, Mi-Young Jeong, Dae-Seung Kim, Yong-Deok Jeon, Yunu Jung, Dong-Hyun Youn, JongWook Kang, Hong-Seob So, Raekil Park, Jong-Hyun Lee, Soyoung Shin, Su-Jin Kim, Jae-Young Um, and Seung-Heon Hong, “Arctigenin Inhibits Adipogenesis by Inducing AMPK Activation and Reduces Weight Gain in High-Fat Diet-Induced Obese Mice,” Journal of Cellular Biochemistry, vol. 117, no. 9, pp. 2067–2077, 2016. View at Publisher · View at Google Scholar
  • A. J. Krentz, K. Fujioka, and M. Hompesch, “Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles,” Diabetes, Obesity and Metabolism, vol. 18, no. 6, pp. 558–570, 2016. View at Publisher · View at Google Scholar
  • Sarah Kim, “Drugs to treat obesity: do they work?: Table 1,” Postgraduate Medical Journal, vol. 92, no. 1089, pp. 401–406, 2016. View at Publisher · View at Google Scholar
  • Miriam Jacome-Sosa, Elizabeth J. Parks, Richard S. Bruno, Esra Tasali, Gary F. Lewis, Barbara O. Schneeman, and Tia M. Rains, “Postprandial Metabolism of Macronutrients and Cardiometabolic Risk: Recent Developments, Emerging Concepts, and Future Directions,” Advances In Nutrition, vol. 7, no. 2, pp. 364–374, 2016. View at Publisher · View at Google Scholar
  • D. Custers, E. Van Hoeck, P. Courselle, S. Apers, and E. Deconinck, “Clustering and diagnostic modelling of slimming aids based on chromatographic and mass spectrometric fingerprints,” Drug Testing and Analysis, 2016. View at Publisher · View at Google Scholar
  • Kristel Lobo Prabhu, and Timothy Jackson, “Overview of Medical and Surgical Treatment of Severe Obesity,” Psychiatric Care in Severe Obesity, pp. 75–82, 2016. View at Publisher · View at Google Scholar
  • Paula Paíga, Manuela J.E. Rodrigues, Manuela Correia, Joana S. Amaral, M. Beatriz P.P. Oliveira, and Cristina Delerue-Matos, “Analysis of pharmaceutical adulterants in plant food supplements by UHPLC-MS/MS,” European Journal of Pharmaceutical Sciences, 2016. View at Publisher · View at Google Scholar
  • Fattore, Murineddu, Salis, Pinna, Fois, Pintore, Asproni, and Diana, “The novel cannabinoid antagonist SM-11 reduces hedonic aspect of food intake through a dopamine-dependent mechanism,” Pharmacological Research, vol. 113, pp. 108–115, 2016. View at Publisher · View at Google Scholar
  • Vidya Narayanaswami, and Linda P. Dwoskin, “Obesity: Current and Potential Pharmacotherapeutics and Targets,” Pharmacology & Therapeutics, 2016. View at Publisher · View at Google Scholar
  • Edward Milbank, M. Carmen Martinez, and Ramaroson Andriantsitohaina, “Extracellular vesicles: Pharmacological modulators of the peripheral and central signals governing obesity,” Pharmacology & Therapeutics, vol. 157, pp. 65–83, 2016. View at Publisher · View at Google Scholar
  • Sani M. Roy, Stacy Rustico, and Bassil Kublaoui, “Prevention and Treatment of Childhood Obesity and Metabolic Syndrome,” Metabolic Syndrome, pp. 829–849, 2016. View at Publisher · View at Google Scholar
  • Marius Zaharia, Lucia Tudorachi, Olga Pintilie, Cristian Drochioi, Robert Gradinaru, and Manuela Murariu, “Banned dinitrophenols still trigger both legal and forensic issues,” Environmental Forensics, vol. 17, no. 1, pp. 120–130, 2016. View at Publisher · View at Google Scholar
  • Yi-Ting Sung, Cheng-Ting Hsiao, I-Jen Chang, Yu-Chih Lin, and Chen-Yu Yueh, “Smoking Cessation Carries a Short-Term Rising Risk for Newly Diagnosed Diabetes Mellitus Independently of Weight Gain: A 6-Year Retrospective Cohort Study,” Journal of Diabetes Research, vol. 2016, pp. 1–7, 2016. View at Publisher · View at Google Scholar
  • Gonçalves Carneiro Spera de Andrade Telma, Emilia Arlindo da Silva Yara, Gazoni Espinoza Diego, Mateus de Lima Leonardo, Karla de Oliveira Cezar Alessandra, Gonçalves Carneiro Spera de Andrade Isabella, de Oliva Neto Pedro, Lainer Palacios Julia, and dos Santos Lucinéia, “Preliminary phytochemical analysis and the effect of Agave sisalana on body weight and defensive behaviours in ovariectomized rats,” Journal of Medicinal Plants Research, vol. 11, no. 34, pp. 538–548, 2017. View at Publisher · View at Google Scholar
  • Kai He, Hang Ma, Heshan Xu, Zongyao Zou, Min Feng, Xuegang Li, and Xiaoli Ye, “Anti-hyperlipidemic effects of Rhizoma Coptidis alkaloids are achieved through modulation of the enterohepatic circulation of bile acids and cross-talk between the gut microbiota and the liver,” Journal of Functional Foods, vol. 35, pp. 205–215, 2017. View at Publisher · View at Google Scholar
  • Samantha Hocking, Anthony Dear, and Michael A. Cowley, “Current and emerging pharmacotherapies for obesity in Australia,” Obesity Research & Clinical Practice, 2017. View at Publisher · View at Google Scholar
  • Thomas Lutz, and Lori Asarian, “Pharmacotherapy for Weight Loss,” Appetite and Food Intake, pp. 277–296, 2017. View at Publisher · View at Google Scholar
  • Thi Thanh Binh Nguyen, Yan Yan Jin, Hea-Jong Chung, and Seong-Tschool Hong, “Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases,” Molecules, vol. 22, no. 11, pp. 1795, 2017. View at Publisher · View at Google Scholar
  • Angela Golden, “Current pharmacotherapies for obesity: A practical perspective,” Journal of the American Association of Nurse Practitioners, vol. 29, no. S1, pp. S43–S52, 2017. View at Publisher · View at Google Scholar
  • C. Pineda Molina, and Badylak, “Translational Smart Materials in Tissue Engineering,” RSC Smart Materials, vol. 2017-, no. 25, pp. 39–66, 2017. View at Publisher · View at Google Scholar
  • Beatriz T. Meneguetti, Marlon H. Cardoso, Camila F. Acosta Ribeiro, Mário R. Felício, Ingrid B. Pinto, Nuno C. Santos, Cristiano Marcelo E. Carvalho, and Octávio L. Franco, “Neuropeptide receptors as potential pharmacological targets for obesity,” Pharmacology & Therapeutics, 2018. View at Publisher · View at Google Scholar
  • Hui Chen, Jane P. M. Ng, David P. Bishop, Bruce K. Milthorpe, and Stella M. Valenzuela, “Gold nanoparticles as cell regulators: beneficial effects of gold nanoparticles on the metabolic profile of mice with pre-existing obesity,” Journal of Nanobiotechnology, vol. 16, no. 1, 2018. View at Publisher · View at Google Scholar
  • Alessandro D. Genazzani, Alessia Prati, and Giulia Despini, “Metabolic Changes and Metabolic Syndrome During the Menopausal Transition,” Pre-Menopause, Menopause and Beyond, pp. 141–152, 2018. View at Publisher · View at Google Scholar
  • Donald E. Greydanus, Marisha Agana, Manmohan K. Kamboj, Saad Shebrain, Neelkamal Soares, Ransome Eke, and Dilip R. Patel, “Pediatric obesity: Current concepts,” Disease-a-Month, 2018. View at Publisher · View at Google Scholar
  • Rukayat Jaji-Sulaimon, Ismail Temitayo Gbadamosi, Gabriel Olaiya Omotoso, Risikat Eniola Kadir, and Fatima A. Sulaimon, “Prenatal exposure to gestational nicotine before neurulation is detrimental to neurodevelopment of wistar rats’ offspring,” Malaysian Journal of Medical Sciences, vol. 25, no. 5, pp. 35–47, 2018. View at Publisher · View at Google Scholar
  • Nicole Remaliah Samantha Sibuyi, Mervin Meyer, Martin Opiyo Onani, Amanda Skepu, and Abram Madimabe Madiehe, “Vascular targeted nanotherapeutic approach for obesity treatment,” International Journal of Nanomedicine, vol. 13, pp. 7915–7929, 2018. View at Publisher · View at Google Scholar
  • Katelyn Opichka, Allen S. Levine, and Chery Smith, “Problematic Eating Behaviors Are More Prevalent in African American Women Who Are Overweight or Obese Than African American Women Who Are Lean or Normal Weight,” Family and Community Health, vol. 42, no. 2, pp. 81–89, 2019. View at Publisher · View at Google Scholar
  • Md. Akil Hossain, Rokeya Pervin, Dipti Debnath, and Mohiuddin Ahmed Bhuiyan, “Therapeutic Treatment for Controlling Childhood Obesity,” Global Perspectives on Childhood Obesity, pp. 377–385, 2019. View at Publisher · View at Google Scholar